Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Aeterna Zentaris Inc.
Type
Public
Traded as NASDAQ: AEZS
TSX: AEZ
Industry Biotechnology
Headquarters Quebec, Canada
Key people
  • Prof. Juergen Engel, Ph.D.
  • Jude Dinges (COO)
Website www.aezsinc.com

Æterna Zentaris Inc. is a Quebec, Canada-based biopharmaceutical drug development company focused in oncology and endocrine therapy, currently investigating treatments for various unmet medical needs. The Company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. It has over 80 employees in Canada, United States and Germany. The company is based in Canada, the development and research site is based in Germany. The company has 3 lead projects: an ongoing Phase 3 trial in multiple myeloma (a form of blood cancer) conducted under a Special Protocol Assessment (SPA): a Phase 3 trial in endometrial cancer with AEZS-108 expected to be initiated in 1Q 2013, and a New Drug Application (NDA) expected to be filed in 1Q 2013 for the approval of AEZS-130 as potentially the first oral diagnostic test for adult growth hormone deficiency (AGHD).

Perifosine: Fast track designation and orphan drug status granted by the FDA. Orphan Medicinal Product designation and positive Scientific Advice granted by the EMA .

AEZS-108: Orphan drug and Orphan medicinal product designations granted by the FDA and EMA respectively, for the treatment of ovarian cancer.

AEZS-130: Orphan drug designation granted by the FDA for use as a diagnostic test for AGHD.

As of December 2013, the company's Chief Commercial Officer is Jude Dinges.


Investment goal date:
Dividends reinvested
Aeterna Zentaris Inc. AEZS report Q2 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q4 2017
2018-03-21
--
--
Q3 2017
2017-11-07
--
--
Q2 2017
2017-08-10
-0.1800
-0.1800
Q1 2017
2017-05-08
-0.3100
-0.3100
Q4 2016
2017-03-15
-0.7100
-0.7100
Q3 2016
2016-11-08
-0.6100
-0.6100
Q2 2016
2016-08-09
-0.7100
-0.7100
Q1 2016
2016-05-09
-0.3700
-0.3700
Q4 2015
2016-03-29
-1.4600
-1.4600
Q3 2015
2015-11-05
-7.0000
-7.0000
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
BANK OF AMERICA CORP /DE/
10
BANK OF MONTREAL /CAN/
48
CITADEL ADVISORS LLC
21100
Creative Planning
2000
DEUTSCHE BANK AG\
58411
JNBA Financial Advisors
91
KCG Holdings, Inc.
18127
LADENBURG THALMANN FINANCIAL SERVICES INC
500
MetLife Securities, Inc
12
RENAISSANCE TECHNOLOGIES LLC
213433
ROYAL BANK OF CANADA
124
TORONTO DOMINION BANK
38
Tower Research Capital LLC (TRC)
1200
UBS Group AG
3122
WELLS FARGO & CO/MN
800
Major Shareholders
Name Relationship
Total Shares
Holding stocks